Integra Lifesciences Holdings Corp (IART) · Sep 8, 2026 · Other events
Refinancing preparation — Previously disclosed 2026 refinancing plan; no terms disclosed
Integra furnished an updated lender presentation tied to its planned 2026 refinancing. The filing confirms preparation, not a completed transaction or improved terms.
This is a financing-process update, not a financing event. The company furnished an updated investor presentation for use with lenders regarding its “previously-disclosed plans to refinance its outstanding senior credit facility in 2026.” 〔0〕 The market already knew refinancing was planned, so the filing adds process confirmation rather than a new catalyst.
The updated deck gives lenders the recovery narrative, but not new financing economics. It highlights LTM Q2 2026 revenue of $1.648 billion, adjusted EBITDA of $337 million, free cash flow of $26 million, and net leverage of 4.1x, while emphasizing Braintree’s ramp, remediation progress, and the expected SurgiMend relaunch. Those figures are presented as publicly available operating information, not newly disclosed deal terms.
The key missing piece is what lenders will actually offer. The filing does not disclose the refinancing amount, maturity, interest rate, covenant changes, lender commitments, or whether the transaction has launched or closed. Net: this confirms that Integra is preparing to refinance while still carrying elevated leverage and a recovery-dependent credit story, but it does not change the standing expectation or establish a new outcome.
Completion of 2026 credit-facility refinancing
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!